Le Lézard
Classified in: Health, Science and technology, Business
Subject: BOARD OF DIRECTORS

Avicanna Announces Resignation of Board Member


/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO, May 07, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that Janet Giesselman has resigned from her role as an independent director of the Company to pursue other opportunities.

The Company thanks Ms. Giesselman for her service and her contributions and wishes her all the best in her future endeavours. The board of directors of the Company is actively engaged in the search for a suitable candidate to fill the vacancy.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and includes statements with respect to the Company's ability find and appoint a suitable candidate for its board of directors. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.



These press releases may also interest you

at 13:30
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS' first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the...

at 13:25
CBL-514 is the first product to treat cellulite at the raised areas.Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034.CBL-0201EFP...

at 13:15
The Board of Governors of the Canadian Memorial Chiropractic College (CMCC) is delighted to announce the appointment of Dr. Christine Bradaric-Baus as its next President, effective July 1, 2024, following the retirement of President...

at 13:13
Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute....

at 13:02
Sorcero, the leading provider of advanced AI solutions purpose-built for life sciences, today announced the release of Scientific Sentiment, enabling Life Sciences teams, for the first time, to quantify product perception across KOLs and the market...

at 13:00
Uwill, the leading mental health and wellness solution for students, proudly announces its inclusion on the prestigious EdTech Digest Awards 'Cool Tool' list for 'Best Higher Education Solution'. This acknowledgement highlights Uwill's commitment to...



News published on and distributed by: